14 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26191358	105	Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).	Euroscreen
25738882	210	Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).	Euroscreen
25247671	30	Development of novel neurokinin 3 receptor (NK3R) selective agonists with resistance to proteolytic degradation.	Kyoto University
7678430	23	Cyclic peptides as selective tachykinin antagonists.	Merck Sharp and Dohme Research Laboratories
16950620	36	N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.	Merck Sharp & Dohme Research Laboratories
8648606	72	Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists.	Cambridge University Forvie Site
7515443	79	Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tachykinin NK-1 receptor.	Universit£
1331460	54	Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-2 receptor agonists.	Glaxo Group Research
1851847	22	Imidazo[4,5-b]quinoxaline cyanines as neurokinin antagonists.	Rochester
21376585	120	Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.	Euroscreen
	10	The dipeptide neurokinin-1 receptor antagonist S19752 is a potent and long-acting inhibitor of bronchoconstriction when administered by aerosol to the guinea pig in vivo	TBA
8759639	33	Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P.	Hebrew University of Jerusalem
8576917	79	3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.	Eli Lilly